Colturato Leandro F, Signorini Filho Roney C, Fernandes Raquel C M, Gebrim Luiz H, Oliani Antônio H
Gynecology and Obstetrics Department, Faculdade de Medicina de São José do Rio Preto, Hospital de Base, São José do Rio Preto, Brazil.
Surgical Oncology Department, Centro de Referência da Saúde da Mulher do Estado de São Paulo, Hospital Pérola Byington, São Paulo, Brazil.
Int J Gynaecol Obstet. 2016 Apr;133(1):69-75. doi: 10.1016/j.ijgo.2015.08.019. Epub 2015 Dec 19.
To evaluate the prevalence of micrometastases in lymph node tissue of patients with stage Ib1-IIA cervical cancer, the correlation of micrometastases with tumor recurrence and survival, and the expression of D2-40 in the primary tumor of patients with recurrence and/or micrometastases and its correlation with histopathologic findings.
In a retrospective study, the medical records of all patients with cervical cancer treated at a hospital in São Paulo, Brazil, between 2001 and 2007 were reviewed. Patients with no lymph node metastases and treated with radical hysterectomy without adjuvant treatment were included. Tumor sections were reviewed and lymph nodes were analyzed with AE1/AE3. Patients with and without recurrence were compared. The presence of lymph node micrometastasis or isolated tumor cells was also evaluated.
Of the 83 patients evaluated, 15 (18%) had recurrence. Significant differences between patients with and without recurrence were observed with regard to tumor greatest axis, clinical stage, number of micrometastases, and negative lymph nodes (P≤0.04). Lymph node micrometastases and isolated tumor cells were significantly different for a stromal invasion depth greater than 2/3 (P=0.046).
The presence of lymph node micrometastases is an important risk factor for tumor recurrence. These patients should be considered eligible for adjuvant radiochemotherapy treatment.
评估Ib1-IIA期宫颈癌患者淋巴结组织中微转移的发生率、微转移与肿瘤复发及生存的相关性,以及复发和/或微转移患者原发肿瘤中D2-40的表达及其与组织病理学结果的相关性。
在一项回顾性研究中,回顾了2001年至2007年期间在巴西圣保罗一家医院接受治疗的所有宫颈癌患者的病历。纳入无淋巴结转移且接受根治性子宫切除术且未接受辅助治疗的患者。对肿瘤切片进行复查,并用AE1/AE3分析淋巴结。比较有复发和无复发的患者。还评估了淋巴结微转移或孤立肿瘤细胞的存在情况。
在评估的83例患者中,15例(18%)复发。在肿瘤最大径、临床分期、微转移数量和阴性淋巴结方面,有复发和无复发的患者之间存在显著差异(P≤0.04)。对于基质浸润深度大于2/3的情况,淋巴结微转移和孤立肿瘤细胞有显著差异(P=0.046)。
淋巴结微转移的存在是肿瘤复发的重要危险因素。这些患者应被视为适合接受辅助放化疗治疗。